Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Seizures 2Glioma 2Epilepsy 1Drug Resistant Epilepsy 1Brain Neoplasms 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × perampanel × Clear all
NCT04497142 2024-08-05

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Dana-Farber Cancer Institute

Phase 1/2 Completed
12 enrolled 8 charts
CNS

Glioma, Seizures

NCT04650204 2023-06-22

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Mayo Clinic

Phase 4 Terminated
4 enrolled 9 charts
CNS

Drug Resistant Epilepsy, Epilepsy, Glioma

NCT02363933 2018-04-27

Perampanel in Seizure Patients With Primary Glial Brain Tumors

Duke University

Phase 4 Completed
9 enrolled 9 charts
CNS

Brain Neoplasms, Seizures

Data powered by HemOnc (CC BY 4.0) Colophon âš¡